Drug Trial Radar · NCT00269880
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
Last checked: Nov 20, 2026Latest source record: May 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,792
Actual
Start
Feb 1995
Primary completion
Dec 1995
Study completion Dec 1995
Sponsor
- Lead sponsor
- Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and effectiveness of abciximab, an anti-platelet therapy, versus placebo in patients undergoing percutaneous coronary intervention when administered in combination with two different heparin regimens. Please see attached results.
Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
Interventions
PlaceboDrug
Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
HeparinDrug
Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
AbciximabDrug
Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death, myocardial infarction, or repeat revascularization within 6 monthsTime frame: up to 6 months
- Death, myocardial infarction, or severe myocardial ischemia leading to urgent repeat percutaneous coronary intervention or urgent coronary artery bypass surgery within 30 daysTime frame: Up to 30 Days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.